Humacyte Inc. (NASDAQ: HUMA) has announced the pricing of an underwritten public offering of 47.6 million shares of common stock at $1.05 per share, with expected gross proceeds of approximately $50 million before underwriting discounts, commissions and offering expenses. The company also granted underwriters a 30-day option to purchase up to an additional 7.1 million shares at the public offering price. The offering is expected to close on or about June 12, 2026, subject to customary closing conditions.
Humacyte stated that it intends to use the net proceeds to support commercialization of Symvess, its first FDA-approved product, which launched commercially in the United States in the first quarter of 2025. Additionally, funds will advance a planned Biologics License Application supplement filing for a hemodialysis indication, fund development of pipeline candidates, and provide working capital for general corporate purposes. This strategic allocation highlights the company's focus on expanding its product reach and advancing its pipeline in regenerative medicine.
Symvess is a bioengineered human tissue developed using Humacyte's novel, scalable technology platform. The company is pioneering off-the-shelf, universally implantable human tissues that aim to improve patient outcomes and transform medical practice. For uses other than the FDA approval in extremity vascular trauma, the acellular tissue engineered vessel (ATEV) remains investigational and not yet approved by the FDA or other regulatory agencies.
Barclays, BTIG, and Titan Partners, a division of American Capital Partners, are serving as joint book-running managers for the offering. The participation of these reputable financial institutions signals confidence in Humacyte's commercial prospects and technology platform.
The implications of this capital raise are significant for the biotechnology sector and for patients awaiting advanced regenerative therapies. The additional funding will enable Humacyte to accelerate the commercialization of Symvess, which could provide a new standard of care in vascular trauma. Moreover, the planned supplement filing for a hemodialysis indication expands the potential patient population, as Symvess could offer an alternative for vascular access in kidney dialysis patients. This addresses a critical unmet need, as many patients suffer from complications related to traditional access methods.
For industry leaders, Humacyte's progress underscores the growing viability of bioengineered tissues and the importance of scalable manufacturing. The company's ability to produce off-the-shelf, universally implantable tissues at commercial scale could disrupt traditional approaches in tissue engineering and organ transplantation. Investors and healthcare executives should monitor Humacyte's commercial execution and regulatory milestones, as success could pave the way for broader adoption of similar technologies.
More details on the offering can be found in the full press release at https://ibn.fm/k6T1b. For further information about Humacyte and its platform, visit the company's website at https://humacyte.com/.
